Neopharmed Gentili announces the private placement of €100.0 million Senior Secured Notes due 2030
Milan, February 14, 2025 – Neopharmed Gentili S.p.A., a joint stock company (società per azioni) incorporated under the laws of Italy (the “Issuer” or “Neopharmed”), has successfully priced €100.0 million of Senior Secured Notes due 2030 (the “New Notes”), in a tap issuance of the high-yield bond issued on April 8, 2024 (the “Tap Issuance”). The issuance and settlement of the New Notes is expected to occur on February 27, 2025, subject to customary closing conditions.
The New Notes will be issued and sold at an issue price of 104.000%. The New Notes will be fungible and have the same terms and conditions as the Issuer’s 7.125% senior secured notes due 2030, issued on April 8, 2024. Upon issuance, the New Notes are expected to be listed on the Official List of the Luxembourg Stock Exchange and admitted to trading on the Euro MTF market thereof.
The proceeds of the Tap Issuance will be mainly used to fund the purchase price of the acquisition of the metoclopramide product portfolio announced on February 4, 2025, to pay fees and expenses in connection with the Tap Issuance, as well as for general corporate purposes.
For further information:
Neopharmed Gentili S.p.A.
Investor Relations
investors@neogen.it
